North America Wegovy Market Size, Share & Trends Analysis Report By Drug Type (Branded Semaglutide, Wegovy  , Generic/Biosimilar Semaglutide , Pipeline biosimilars  ), By Route of Administration (Subcutaneous Injection, Oral Formulations), By Country (U.S., Canada) and Forecast, 2026-2034

North America Wegovy Market Trends

Oral GLP-1 Adoption and Higher-Dose Therapy Reshape Treatment

Oral delivery is accelerating patient access alongside established once-weekly injections. Wegovy pill became broadly available in the United States in January 2026 through 70,000+ pharmacies, with approximately 1.3 million prescriptions during Q1 2026 and more than 3 million prescriptions within five months. Weekly prescriptions exceeded 200,000 by April, demonstrating rapid adoption among patients seeking alternatives to injectable therapy.

Technology development is simultaneously moving toward higher-dose formulations. The FDA approved once-weekly 7.2 mg Wegovy HD in March 2026; the STEP UP program reported 20.7% mean weight reduction, while approximately one-third of participants achieved weight loss of at least 25%. The expanding oral-plus-injectable platform therefore increases treatment flexibility while supporting demand across obesity clinics, primary care, pharmacies, and home-treatment settings.

North America Wegovy Market Drivers

Expanding Obesity Treatment Access and Prescription Volumes

Large untreated populations and broader delivery options are driving pharmacological weight-management adoption. More than 100 million U.S. adults live with obesity, while the oral Wegovy launch exceeded 3 million prescriptions within roughly five months and reached a pace equivalent to about 1 prescription every 5 seconds. Clinical efficacy also supports uptake: oral semaglutide produced approximately 17% weight reduction among treatment-adherent participants, while 7.2 mg injectable semaglutide delivered 20.7% mean weight loss and at least 25% loss for around one-third of STEP UP participants.

North America Wegovy Market Restraints

Treatment Costs, Tolerability and Competitive Pressure Limit Uptake

Affordability and treatment tolerability remain significant constraints. Novo Nordisk introduced a USD 149 monthly starting-dose self-pay offer for oral Wegovy in 2026, illustrating continued sensitivity to out-of-pocket expense. Patient-experience research covering 410,198 online posts and 67,008 self-reported users found 43.5% mentioning at least one side effect; nausea appeared in 36.9%, fatigue in 16.7%, vomiting in 16.3%, constipation in 15.3%, and diarrhea in 12.6%. These factors can influence persistence and switching behavior.

North America Wegovy Market Opportunities

Oral Therapy and Generic Entry Expand Addressable Patient Access

Formulation diversification and generic entry create substantial access opportunities. Oral Wegovy reached more than 3 million U.S. prescriptions within five months, while the majority of new prescriptions reportedly involved people previously untreated with GLP-1 therapy. In Canada, Health Canada authorized the first generic semaglutide for weight loss in June 2026 and was reviewing 6 additional submissions; generic medicines in Canada can typically cost 45%–90% less than branded equivalents. These developments could broaden treatment access across retail, online, specialty, and public reimbursement channels.

Challenges in North America Wegovy Market

Scaling Supply While Managing Rapid Product Diversification

Manufacturers must balance injectable capacity, oral formulations, higher-dose products, and emerging generics while prescription volumes accelerate. Wegovy pill exceeded 200,000 weekly prescriptions by April 2026, surpassed 3 million cumulative prescriptions by June, and subsequently exceeded 265,000 weekly prescriptions in July. Canada simultaneously progressed from its first generic semaglutide authorization in April to additional approvals in May and June, with 6 weight-loss generic submissions still under review after the June authorization, increasing manufacturing, pricing, and portfolio-management complexity.

North America Wegovy Market Segmentation

The market is segmented by drug type, route of administration, dosage strength, patient demographics, BMI category, distribution channel, application/indication, end user, and pricing tier. Among categories for which numerical input was supplied, branded semaglutide dominates with 48.67% of the 2026 drug-type total, followed by Wegovy at 25.76%, generic/biosimilar semaglutide at 15.68%, and pipeline biosimilars at 9.88%.

By Drug Type

Branded semaglutide is the largest category, increasing from USD 619.05 million in 2025 to USD 793.62 million in 2026 and USD 5,790.53 million by 2034 at a 28.20% CAGR. Its 2026 contribution equals 48.67% of the supplied drug-type total.

Wegovy is the fastest-growing listed category at 29.40% CAGR, moving from USD 420.07 million in 2026 to USD 3,302.15 million by 2034. Generic/biosimilar semaglutide records 28.70% CAGR, while pipeline biosimilars record 26.70%.

By Route of Administration

Subcutaneous injection remains the established treatment format across 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg/week titration strengths. Oral formulations are emerging rapidly, supported by the 25 mg Wegovy tablet and millions of U.S. prescriptions in 2026. Numerical market values and segment CAGRs were not supplied for this segmentation.

By Dosage Strength

The segmentation spans 0.25 mg/week through 2.4 mg/week, representing a nearly tenfold difference between initiation and maintenance doses. The established 2.4 mg/week maintenance formulation anchors chronic weight management, while titration through 0.25 mg, 0.5 mg, 1 mg, and 1.7 mg supports tolerability. No input-table CAGR was supplied by dosage strength.

By Patient Demographics

Adults constitute the core treated population, while elderly and adolescent patients broaden the addressable base. In Canada, generic semaglutide for weight management was authorized for patients 12 years and older, illustrating expanding adolescent access. No numerical demographic market value or CAGR was supplied.

By BMI Category

Treatment demand spans patients with BMI 27–29.9 with qualifying comorbidities and patients with BMI ≥30, creating distinct overweight and obesity populations. The latter represents the principal obesity-treatment pool, although the supplied tables provide no BMI-specific revenue or CAGR.

By Distribution Channel: Retail pharmacies, hospital pharmacies, online pharmacies, and specialty clinics collectively support access. The U.S. oral launch reached 70,000+ pharmacies, demonstrating the scale available through retail and digitally supported channels. No distribution-channel revenue or CAGR was provided.

By Application/Indication

Obesity management is complemented by type 2 diabetes with obesity, cardiovascular risk reduction, and metabolic syndrome. Wegovy 2.4 mg is approved in the United States for weight management and cardiovascular risk reduction, expanding use beyond body-weight outcomes. No indication-level market CAGR was supplied.

By End User

Hospitals, ambulatory surgical centers, weight-management clinics, and home-care settings form the principal end-user groups. Once-weekly injections and once-daily oral therapy increase home-based treatment feasibility, while 70,000+ pharmacy locations broaden decentralized access. No end-user market value or CAGR was supplied.

By Pricing Tier

High-, middle-, and low-income market tiers reflect differences in reimbursement and self-pay capacity. A USD 149 per month, approximately USD 5 per day, introductory self-pay offer illustrates pricing strategies designed to improve accessibility. No pricing-tier market value or CAGR was supplied.

North America Wegovy Market Counties Outlook

1. U.S.

The United States contributes 77.23% of the supplied 2026 country total, increasing from USD 984.05 million in 2025 to USD 1,251.81 million in 2026 and forecast to reach USD 8,584.37 million by 2034 at a 27.21% CAGR. Prescription infrastructure includes more than 70,000 pharmacy locations, while oral Wegovy surpassed 3 million prescriptions within five months of its January 2026 launch.

The U.S. portfolio increasingly spans oral, standard injectable, and higher-dose injectable therapy. Wegovy HD 7.2 mg entered the market in April 2026 after FDA approval, supplementing the established 2.4 mg formulation and strengthening treatment options across obesity management and specialist care.

2. Canada

Canada represents 22.77% of 2026 country revenue, advancing from USD 285.53 million in 2025 to USD 369.16 million in 2026 and a forecast USD 2,882.28 million by 2034. Its 29.29% CAGR exceeds the U.S. rate by 2.08 percentage points.

Generic competition is becoming a defining country-level factor. Canada became the first G7 country to authorize generic semaglutide in April 2026, followed by further approvals; by June, Health Canada had authorized a generic semaglutide injection specifically for weight loss and was reviewing 6 additional submissions. Potential generic discounts of 45%–90% may support wider penetration.

Top players in North America Wegovy Market

• Novo Nordisk A/S
• Eli Lilly and Company
• Apotex Inc.
• Dr. Reddy's Laboratories Ltd.
• Sandoz Group AG
• Teva Pharmaceutical Industries Ltd.
• Viatris Inc.
• Amgen Inc.
• Pfizer Inc.
• AstraZeneca plc
• Boehringer Ingelheim
• Roche Holding AG

Top Two Companies

• Novo Nordisk A/S

Novo Nordisk occupies the central competitive position through the Wegovy franchise, spanning standard injectable semaglutide, the 25 mg oral tablet, and 7.2 mg Wegovy HD. Wegovy pill surpassed 3 million U.S. prescriptions within five months, and weekly prescriptions exceeded 265,000 by July 2026. The company also reported approximately 20.7% mean weight loss with 7.2 mg therapy. Exact company revenue share of the supplied North American dataset was not provided and therefore is not fabricated; however, its branded portfolio directly addresses the USD 793.62 million branded-semiglutide category, representing 48.67% of the supplied 2026 drug-type total.

• Eli Lilly and Company

Eli Lilly represents the principal branded obesity-therapy competitor through its tirzepatide portfolio and expanding oral GLP-1 strategy. In Q2 2026, company revenue reportedly increased 48% to USD 22.97 billion, while management raised its annual revenue outlook to USD 85–87 billion amid strong GLP-1 demand. This competitive pressure is particularly relevant as Wegovy's listed category expands at 29.40% CAGR through 2034. An exact Lilly percentage of North American Wegovy-related revenue is not contained in the mandatory dataset and is therefore not assigned; positioning is based on its role as a major competing obesity-drug manufacturer.

Recent Developments in North America Wegovy Market

• 2026: On January 5, Novo Nordisk broadly launched Wegovy pill in the United States through 70,000+ pharmacies, with a USD 149 monthly starting-dose self-pay offer.
• 2026: In March, the FDA approved 7.2 mg once-weekly Wegovy HD after STEP UP demonstrated 20.7% mean weight loss and ≥25% weight reduction in around one-third of participants.
• 2026: In April, Canada became the first G7 country to approve generic semaglutide, with 8 additional generic submissions then under Health Canada review.
• 2026: In June, Wegovy pill crossed 3 million U.S. prescriptions within approximately five months, equivalent to roughly 1 prescription every 5 seconds.
• 2026: On June 29, Health Canada authorized Apotex's Sevmia generic semaglutide for weight management in patients aged 12+, while 6 additional submissions remained under review.

Research Methodology

The assessment uses 2025 as the base year, 2026 as the current year, historical analysis covering 2022–2024, and forecasts through 2034. Mandatory supplied numerical tables were treated as the primary quantitative source: the country dataset reports USD 1,269.58 million for 2025, USD 1,620.97 million for 2026, and USD 11,466.65 million for 2034 at 27% CAGR, while the separately supplied drug-type table reports USD 1,630.58 million in 2026 and USD 12,087.78 million in 2034 at 28.25% CAGR. Calculated percentages use only these supplied values; external regulatory, corporate, and industry sources were used for product launches, prescription volumes, clinical outcomes, competition, and recent developments without overriding the mandatory forecast data.